Title:
EP2 ANTAGONIST
Document Type and Number:
WIPO Patent Application WO/2022/138791
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic activity against the EP2 receptor. A compound represented by general formula (I) (wherein all symbols have the same meanings as the symbols described in the description) or a pharmaceutically acceptable salt thereof is useful as a medicinal ingredient, which has a potent antagonistic activity against an EP2 receptor, for the prevention and/or treatment of a disease caused by activation of the EP2 receptor.
Inventors:
WATANABE AKIO (JP)
HIROOKA YASUO (JP)
TSUBOI KAZUMA (JP)
HIROOKA YASUO (JP)
TSUBOI KAZUMA (JP)
Application Number:
PCT/JP2021/047769
Publication Date:
June 30, 2022
Filing Date:
December 23, 2021
Export Citation:
Assignee:
ONO PHARMACEUTICAL CO (JP)
International Classes:
C07D207/34; A61K31/166; A61K31/397; A61K31/40; A61K31/4155; A61K31/4427; A61K31/451; A61K31/519; A61K31/5355; A61K31/5377; A61K31/54; A61K45/00; A61P1/04; A61P9/10; A61P9/12; A61P13/12; A61P15/00; A61P17/10; A61P19/02; A61P19/06; A61P21/00; A61P25/04; A61P25/16; A61P25/28; A61P29/00; A61P29/02; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P43/00; C07D401/06; C07D401/12; C07D403/12; C07D403/14; C07D405/04; C07D405/06; C07D487/04; C07D491/048
Domestic Patent References:
| WO2020059790A1 | 2020-03-26 | |||
| WO2005080367A1 | 2005-09-01 | |||
| WO2020262603A1 | 2020-12-30 |
Foreign References:
| JP2009505973A | 2009-02-12 | |||
| JP2015520738A | 2015-07-23 | |||
| US20110201684A1 | 2011-08-18 |
Other References:
DATABASE REGISTRY 25 March 2014 (2014-03-25), ANONYMOUS : "Benzeneacetic acid, 3-[[[1-(2-phenylethyl)-1H-pyrrol-2-yl]carbonyl]amino]- (CA INDEX NAME) ", XP055946357, retrieved from STN Database accession no. 1572942-47-2
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: